4//SEC Filing
Abdul-Ahad Wajdi 4
Accession 0001493152-20-009961
CIK 0001460702other
Filed
May 26, 8:00 PM ET
Accepted
May 27, 6:07 PM ET
Size
8.3 KB
Accession
0001493152-20-009961
Insider Transaction Report
Form 4
Abdul-Ahad Wajdi
VP, R&D, CSO
Transactions
- Other
Warrant (Right to Buy)
2020-05-22+7,971→ 7,971 totalExercise: $2.07From: 2020-05-22Exp: 2024-01-31→ Common Stock (7,971 underlying) - Other
Warrant (Right to Buy)
2020-05-22+8,857→ 8,857 totalExercise: $2.54From: 2020-05-22Exp: 2025-03-02→ Common Stock (8,857 underlying)
Footnotes (2)
- [F1]On May 22, 2020, a reverse merger transaction between the Issuer and Qualigen, Inc. ("Qualigen") was consummated such that Qualigen became a wholly-owned subsidiary of the Issuer (the "Merger"). Pursuant to and effective as of the closing of the Merger (the "Closing"), the Reporting Person became an officer of the Issuer.
- [F2]Immediately prior to the Closing, the Reporting Person held Qualigen Series C convertible preferred stock warrants. Pursuant to the Merger, the Qualigen Series C convertible preferred stock warrants previously held by the Reporting Person were assumed by the Issuer and may be exercised solely for shares of common stock of the Issuer.
Documents
Issuer
Qualigen Therapeutics, Inc.
CIK 0001460702
Entity typeother
Related Parties
1- filerCIK 0001812749
Filing Metadata
- Form type
- 4
- Filed
- May 26, 8:00 PM ET
- Accepted
- May 27, 6:07 PM ET
- Size
- 8.3 KB